Observ Medical

[Quadruple]

Ja, det blir spennende. Hvis de leverer strålende tall så har de lurt markedet. Igjen.
For svært lite er blitt meldt. Og Observe (og andre små håpefulle selskaper) er vanligvis ikke tilbakeholdne med å melde alt som kan oppfattes positivt.

[Powertrade]

La oss håpe. De har iallefall et produkt, - som selges - et marked med behov - og muligens en portefølje som kan komme i salgsloopen etterhvert. Det er da noe

[TekBot]

Observe Medical secures framework agreement in Scotland for Unometer[TM] 500

Oslo, March 11, 2024 - Observe Medical ASA (the “Company” or “Observe Medical”)
announces that the Group, via its UK distributor C&P Medical, has been awarded
onto the Scottish NHS Urology Framework with Unometer[TM ]500. This is a 3 year
…

Vis børsmeldingen

contract until end of March 2027, effective from April 2024.

NHS Scotland consists of 14 geographically based local NHS boards with over 180
individual NHS hospitals containing more than 13,000 available staffed beds for
acute specialities.NHS Scotland has historically ordered more than 150,000 units
annually of Unometer[TM] of a total UK market of approximately 800,000 units
annually. Anticipating a continuation of this strong demand, this new Framework
agreement holds the potential to generate annual revenues exceeding NOK 13
million.

Building on the recent announcement made on September 11, 2023, regarding
Observe Medical’s acquisition of trademarks and other intellectual property
rights for the UnometerT and Abdo-PressureT products, we are thrilled to unveil
this major agreement with NHS Scotland for distribution of our UnometerT 500
product. This marks a substantial milestone in the ongoing development of the
UnometerT business, which has traditionally generated annual revenues exceeding
NOK 200 million.

“I am proud of the entire Observe Medical team who, through dedicated work, have
enabled us to be in a position to deliver Unometer[TM ]500 products to NHSSC. I
would also like to applaud our UK distributor, C&P Medical, who through their
expertise have been crucial during this process. This agreement underscores the
strength and market position of high-quality products such as our
Unometer[TM ]portfolio”, said Jørgen Mann, Interim CEO at Observe Medical.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Terje Bakken, Chairman Observe Medical
Mobile: +47 934 33 321
E-mail: tb@reitenco.no

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care,
in combination with targeted M&A.

The Company is headquartered in Oslo, Norway, with additional offices in Narvik,
Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In
addition, Observe Medical has a direct sale organization in the Nordics and a
distributor network internationally.

Further information is available at www.observemedical.com.

Kilde

[Powertrade]

Fantastisk - more to come

[Sjakk]

ja jøss, en melding fra obsrv med konkrete tall, kommer det flere av de så kan jeg nesten miste pennystock feelingen. Jeg gjetter vilt her nå, unometer er plastposer til 85kr stykket? (NHS scotland historically, potential annual revenues 13Mnok / 150k units = 86kr)

[Powertrade]

Sista sjance til å kjøpe OBSERVE MEDICAL på disse lave nivåene

I morgen kan vi fort se 0,6 + og utover året vil vi krype opp mot 1 krone

100%oppside- MINST

Gleder meg til Q-rapporten i morgen

[Powertrade]

Invitation to Observe Medical ASA second half and full year 2023 presentation and Q&A

Oslo, March 6, 2024 -Observe Medical (“the Company” or “Observe Medical”) will

release its results for the second half and full year 2023 on Wednesday, 13
March 2024. The presentation will be published on NewsWeb and theCompany’s

[Rodjer]

Selskapet framstår uten tvil mer spennende enn på utrolig lang tid.
Veldig spent på å høre hva de sier om utsiktene framover nå, uten tvil ser mye av businessen ut til endelig å løsne hvertfall.

[Quadruple]

Nå kan de kanskje ikke lenger regne med støtte fra Ingerø Reiten heller?
Reiten er ikke lenger i en situasjon der de kan bruke penger på risiko-prosjekter, og skulle nok gjerne sett at de 50 mill. brukt på Observe var ugjort.

[Quadruple]

@Rodjer

uten tvil ser mye av businessen ut til endelig å løsne hvertfall.

Vet ikke hvor du har det fra? Men imorgen vet vi kanskje alle litt mer.

[Rodjer]

Om man ser på nyhetene før og etter emi hersker det vel ingen tvil om at noe har løsnet.
Hva det gir av inntekter i q4 er nok moderat men burde love godt for 2024

[Quadruple]

De har meldt salg for ca 0,5 mill. siden emi. De har meldt avtaler, men ingen håndfaste tallfestede kontrakter. Mulig de har fått til mer enn de har publisert, det vil vise seg imorgen.

[TekBot]

Observe Medical ASA: Full year and second half 2023 results

Oslo, March 13, 2024 - Observe Medical (“the Company” or “Observe Medical”)
today releases its results for the full year and second half of 2023.

…

Vis børsmeldingen

Business update

The strategic acquisition of trademarks and intellectual property rights for the
UnoMeterT portfolio from Convatec, coupled with the CE certification of
UnoMeterT 500, marked 2023 as a transformative year for Observe Medical. These
milestones laid a strong groundwork for the company’s commercial growth.

In a year of commercial milestones, Observe Medical achieved growth and market
expansion in 2023. We launched and delivered our first UnoMeterT Abdo-Pressure
and UnoMeterT 500 products, demonstrating our capacity to meet market demand.
Also, we expanded our distribution network to cover more than 20 countries,
accounting for a substantial portion of historic Convatec sales territories.

Financial highlights

In the second half of 2023 (H2 2023), operating revenues increased to 16.1 MNOK,
demonstrating an 8.6 MNOK improvement year-over-year (YoY). For the full year
2023 (FY 2023), revenues climbed to 27.9 MNOK, reflecting an 8.4 MNOK increase
YoY.

Gross profit in H2 2023 increased, reaching 5.0 MNOK, up by 4.6 MNOK YoY. The FY
2023 gross profit was 9.3 MNOK, showing a solid increase of 4.1 MNOK YoY.

Despite the negative EBITDA figures, there has been a noticeable improvement. H2
2023’s EBITDA was -14.9 MNOK, which is a positive change of 12.3 MNOK compared
to H2 2022. The FY 2023 EBITDA also improved by 10.8 MNOK YoY.

The net result shows a reduction in losses, with H2 2023 posting a loss of
25.159 MNOK, which is an 8.469 MNOK improvement over H2 2022. The FY 2023 net
loss of 60.354 MNOK is also an improvement of 9.553 MNOK over FY 2022.

As announced on December 12, 2023, the Company completed a rights issue raising
a total of 35.7 MNOK, which included 21.5 MNOK in cash contributions.

Presentation

The Company will host a presentation and Q&A session at 08:30 CET today.
Personal attendance is welcomed at Olav Vs gate 5, 0161
Oslo (https://www.google.com/maps/place/data=!4m2!3m1!1s0x46416e80b0b4d189:0x5427
c113c334e02e?sa=X&ved=2ahUKEwjAx9nap86EAxVZIxAIHc_WAg4Q4kB6BAhFEAA). The
presentation will also be available via webcast at the following link:

https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20240313_1

After the live event, the presentation and recording will be made
available under the Investor Relations section on the Company’s website,

Investor relations – Observe Medical

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, Finance Manager Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care,
in combination with targeted M&A.

The Company is headquartered in Oslo, Norway, with additional offices in Narvik,
Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In
addition, Observe Medical has a direct sale organization in the Nordics and a
distributor network internationally.

Further information is available at www.observemedical.com.

Kilde

[Powertrade]

Herlig- det går frem og opp. Meget spennende utsikter for 2024. Ser nok krona om ikje så alt for lenge !

[Midlang86]

Tja 13 mill i cash pr 31.12.23. Med andre ord tomt nå om ikke skuta er snudd til at sales dekker kostnader?

[Powertrade]

Da får vi putte inn litt mer om det trengs…

[Powertrade]

Profesjonell og tillitsvekkende 2023 presentasjon. Lover bra for fremtiden

Når media kommer på banen - vil det allerede vært kjørt analyser fra meglerfirma. Den smarte investor er inne før dette kommer ut - og kanskje før bjellesauene går inn
Lykke til

[Quadruple]

Vær forberedt på emisjon som må komme snart. Det lille de fikk inn i emisjonen i desember er nok snart oppbrukt, selvom det ikke var tema i dagens presentasjon. Og det renner fortsatt ut betydelig mer enn det som kommer inn.

[Powertrade]

Jeg er klar

[TekBot]

Observe Medical ASA - Mandatory notification of trade

15 March 2024, Observe Medical ASA (the “Company”): Soleglad Invest AS (a
closely related party to Kathrine Gamborg Andreassen, director of the board of
directors in the Company), has on 14 March 2024 sold 200,600 shares in the
…

Vis børsmeldingen

Company at an average price of NOK 0.42.

Following the sale, Soleglad Invest AS holds 818,760 shares in the Company. Copy
of notification is attached hereto.

Kilde